Keyword results: DHSC

PREMIUM CONTENT

Novacyt – receives £134.6 million claim from Government – this is all to do with the bonus of ex CEO Graham Mullis and stinks.

As folks guzzled on the covid testing hype, one man grew very rich. Graham Mullis was CEO of Novacyt (NCYT), a nothing biotech perennial dog, which just happened to have a test. Mullis was to be awarded a cash bonus, the size of which was dependent on the share price as of October 17 2020.

Subscribe to ShareProphets to access Premium Content
ODX
ODX
PREMIUM CONTENT

Omega Diagnostics – how close to tits up? Placing process surely now underway - Why not ‘fess up?

You do not need the brains of, the amazing, Rachel Riley to work out that Omega Diagnostics (ODX) needs to do a placing PDQ or it is in serious danger of going tits up, But for those Bulletin Board Morons who, having the brains of a park bench, are in denial here are the maths:

Subscribe to ShareProphets to access Premium Content
ODX
ODX
PREMIUM CONTENT

Omega Diagnostics hit with a £2.5 million bill after the government terminates its contract

The last time I wrote about Omega Diagnostics (ODX) was back in June when I got slated for suggesting that the company had missed the boat when it came to Covid testing, and that its Department of Health and Social Care contract wasn’t worth the headline figure you so often saw people banging on about!

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

Abingdon sings at the Covid bailout placing ball, next up Omega Diagnostics then Abingdon again?

Abingdon Health (ABDX) will, no doubt, claim that its up to £6 million placing, open offer and Primary Bid offer at 25p is down solely to the DHSC not paying delayed bills. But then again this was a company that was technically insolvent before it raised £20 million at is IPO a year ago so, in my view, it has always been a basket case and I have explicitly warned you many times that a bailout was looming. For the record, this will not be the last one. So, who is next? Abingdon again or the other grossly overhyped covid dog Omega (OMX). But first a covid prediction…

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

Novacyt admits possibly loss making – a reminder of that porcine executive bonus plan

You may remember that directors of Novacyt (NCYT) made an abosolute killing because of a cash bonus plan which was dependent on the share price at October 17 2020. Assisted enormously by news of a massive contract win with the DHSC announced on September 29 the shares were c930p on D day. Today they are 325p as the horror of the DHSC feck up emerges. As a reminder here is what Novacyt said on 29 September sending its shares roofing it:

Subscribe to ShareProphets to access Premium Content
ODX
ODX
PREMIUM CONTENT

Will Covid testing be around long enough for companies like Omega Diagnostics to justify their valuations? I doubt it!

I’ve recently found myself wondering how many of these ‘Covid stocks’ have missed the boat, as many of them still aren’t producing any significant amounts of revenue, yet often their markets caps are comparatively very high.

Subscribe to ShareProphets to access Premium Content
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments

|